Protein Disulfide Isomerase Disassembles TDP-43/G3BP1 Condensates and Antagonizes TDP-43 Pathological Aggregates

  • Adv Sci (Weinh). 2026 Jul;13(38):e16846. doi: 10.1002/advs.202516846.
Jia-Qi Liu  1 Hao Liu  1 Yu-Xuan Sun  1 Yuying Li  2 Xiangyi Liu  3 Li-Qiang Wang  1 Zhaofei Yang  4 Qi Fu  5 Xiaojiao Xu  6 Jie Chen  1 Yingshuang Zhang  3 Jun Zhou  5 Weidong Le  6 Mengchao Cui  2  7 Yi Liang  1
Affiliations
  • 1. Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, China.
  • 2. Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China.
  • 3. Department of Neurology, Peking University Third Hospital, Beijing, China.
  • 4. Liaoning Provincial Key Laboratory for Research on the Pathogenic Mechanisms of Neurological Diseases, the First Affiliated Hospital, Dalian Medical University, Dalian, China.
  • 5. Hubei Key Laboratory of Bioinorganic Chemistry & Materia Medica, Hubei Engineering Research Center for Biomaterials and Medical Protective Materials, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, Wuhan, China.
  • 6. Institute of Neurology, Sichuan Academy of Medical Sciences-Sichuan Provincial Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, China.
  • 7. Center For Advanced Materials Research & Faculty of Arts and Sciences, Beijing Normal University At Zhuhai, Zhuhai, China.
Abstract

Cytoplasmic mislocalization and aggregation of transactive response DNA-binding protein-43 (TDP-43) is a common pathological feature of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration, and Alzheimer's disease with TDP-43 pathology (AD-TDP); the exact role of protein disulfide isomerase (PDI), an enzyme with chaperone activity, in modulating the pathological behavior of TDP-43 is unknown. In this study, we report that wild-type PDI, through its specific interaction with TDP-43, markedly attenuates phase separation of TDP-43, competitively displaces G3BP1 to disassemble TDP-43/G3BP1 condensates, and further counteracts the pathological mislocalization, abnormal phosphorylation, and pathological aggregation of TDP-43 through the b' domain of the enzyme. Ultimately, this alleviates mitochondrial damage and neuronal toxicity caused by TDP-43 aggregation and suppresses UNC13A cryptic splicing in stressed cells. In the presence of abnormal forms of PDI, however, PDI loses its activity, and stress granules containing TDP-43 are assembled into amyloid fibrils, resulting in mitochondrial impairment and neuronal cell death in ALS and AD-TDP patients. These findings not only provide new insights into the pathogenic mechanisms of TDP-43 in neurodegenerative diseases such as ALS and AD-TDP, but also propose PDI as a potential therapeutic target.

Keywords
TDP‐43; amyotrophic lateral sclerosis; mitochondrial impairment; protein aggregation; protein disulfide isomerase; protein phase separation.
Products